Agios Pharmaceuticals Inc Financials
Agios Pharmaceuticals Inc (AGIO) reported $54.0M in revenue for fiscal year 2025, up 48.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Agios still operates as a cash-funded research platform, with rising product revenue far too small to absorb its expense base.
Over the last three fiscal years, revenue roughly doubled to$54M , but operating cash burn still ran at-$373M ; that gap shows sales growth has not yet changed the financing model. Free cash flow remained close to operating cash flow, so the cash drain comes mainly from R&D and overhead rather than a capex-heavy buildout.
The balance sheet is unusually liquid for a money-losing company: current assets of
Reported profit appeared in one recent year at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Agios Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Agios Pharmaceuticals Inc scores 10.26, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.9B) relative to total liabilities ($104.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Agios Pharmaceuticals Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Agios Pharmaceuticals Inc reported a net loss of $413.0M while operations used $373.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Agios Pharmaceuticals Inc generated $54.0M in revenue in fiscal year 2025. This represents an increase of 48.0% from the prior year.
Agios Pharmaceuticals Inc's EBITDA was -$466.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.2% from the prior year.
Agios Pharmaceuticals Inc reported -$413.0M in net income in fiscal year 2025. This represents a decrease of 161.3% from the prior year.
Agios Pharmaceuticals Inc earned -$7.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 161.2% from the prior year.
Cash & Balance Sheet
Agios Pharmaceuticals Inc recorded an outflow of $377.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 3.6% from the prior year.
Agios Pharmaceuticals Inc held $89.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Agios Pharmaceuticals Inc's gross margin was 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.
Agios Pharmaceuticals Inc's ROE was -34.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 78.4 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Agios Pharmaceuticals Inc invested $339.5M in research and development in fiscal year 2025. This represents an increase of 12.7% from the prior year.
Agios Pharmaceuticals Inc invested $4.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 156.1% from the prior year.
Not reported for fiscal year 2025.
AGIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $98.3M | $54.0M+48.0% | $36.5M+36.1% | $26.8M+88.4% | $14.2M | $0 | $0-100.0% | $117.9M+24.9% | $94.4M+119.4% | $43.0M-38.5% | $69.9M+18.2% | $59.1M-9.5% | $65.4M+155.8% | $25.5M+1.8% | $25.1M+15.0% | $21.8M |
| Cost of Revenue | $7.9M | $6.3M+52.3% | $4.2M+44.6% | $2.9M+69.1% | $1.7M | $0 | $0-100.0% | $1.3M-5.7% | $1.4M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $90.5M | $47.7M+47.5% | $32.3M+35.0% | $23.9M+91.0% | $12.5M | $0 | $0-100.0% | $116.6M+25.4% | $93.0M+116.2% | $43.0M-38.5% | $69.9M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $356.8M | $339.5M+12.7% | $301.3M+1.9% | $295.5M+5.6% | $279.9M+8.9% | $257.0M+16.4% | $220.8M+3.1% | $214.3M-37.2% | $341.3M+16.6% | $292.7M+32.9% | $220.2M+55.2% | $141.8M+41.3% | $100.4M+84.2% | $54.5M+32.8% | $41.0M+31.3% | $31.3M |
| SG&A Expenses | $192.7M | $180.3M+15.0% | $156.8M+30.8% | $119.9M-1.5% | $121.7M+0.2% | $121.4M+5.5% | $115.1M+12.8% | $102.0M-10.6% | $114.1M+60.5% | $71.1M+40.2% | $50.7M+40.9% | $36.0M+88.2% | $19.1M+92.6% | $9.9M+40.6% | $7.1M-2.1% | $7.2M |
| Operating Income | -$459.0M | -$472.1M-10.9% | -$425.7M-8.7% | -$391.5M-0.6% | -$389.0M-2.8% | -$378.4M-12.7% | -$335.9M-6.2% | -$316.3M+12.7% | -$362.5M-13.0% | -$320.8M-59.6% | -$201.0M-69.3% | -$118.7M-119.3% | -$54.1M-39.2% | -$38.9M-69.1% | -$23.0M-38.3% | -$16.6M |
| Income Tax | N/A | -$1.0M-102.3% | $44.2M | $0 | $0 | N/A | N/A | $0 | $0 | $0 | $0 | $0+100.0% | -$426K-173.6% | $579K+120.5% | -$2.8M-139.2% | $7.2M |
| Net Income | -$411.5M | -$413.0M-161.3% | $674.0M+291.5% | -$352.0M-51.7% | -$232.0M-114.5% | $1.6B+590.3% | -$327.4M+20.4% | -$411.5M-18.9% | -$346.0M-10.0% | -$314.7M-58.5% | -$198.5M-68.6% | -$117.7M-120.0% | -$53.5M-35.8% | -$39.4M-96.0% | -$20.1M+15.2% | -$23.7M |
| EPS (Diluted) | — | -$7.12-161.2% | $11.64+283.9% | -$6.33-49.6% | -$4.23-115.9% | $26.55+660.1% | -$4.74+30.9% | -$6.86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AGIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B-22.0% | $1.7B+77.5% | $937.1M-24.3% | $1.2B-13.8% | $1.4B+68.6% | $853.0M-4.2% | $890.7M+3.8% | $858.5M+39.7% | $614.4M-0.8% | $619.1M+47.4% | $420.1M-14.6% | $491.9M+144.5% | $201.2M+46.9% | $137.0M | N/A |
| Current Assets | $942.1M-2.4% | $965.6M+15.8% | $833.8M+0.1% | $832.8M-21.7% | $1.1B+67.2% | $636.7M+4.1% | $611.7M-0.3% | $613.8M+37.8% | $445.3M-20.5% | $559.9M+66.0% | $337.3M-6.2% | $359.5M+111.8% | $169.7M+30.4% | $130.1M | N/A |
| Cash & Equivalents | $89.1M+16.9% | $76.2M-13.6% | $88.2M-36.7% | $139.3M-31.4% | $203.1M+59.4% | $127.4M+57.5% | $80.9M+14.8% | $70.5M-31.4% | $102.7M-36.1% | $160.8M+124.0% | $71.8M+411.5% | $14.0M-80.4% | $71.6M-21.6% | $91.3M-22.4% | $117.7M |
| Inventory | $32.9M+19.2% | $27.6M+44.8% | $19.1M+124.6% | $8.5M | $0-100.0% | $14.7M+100.5% | $7.3M+743.6% | $869K | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $104.1M-14.8% | $122.2M-3.1% | $126.1M-8.6% | $137.9M-5.4% | $145.8M-67.9% | $453.5M+81.2% | $250.2M+46.4% | $170.9M-28.5% | $238.9M-8.3% | $260.5M+247.6% | $74.9M+11.0% | $67.5M-3.1% | $69.7M-66.6% | $209.0M | N/A |
| Current Liabilities | $82.2M+1.3% | $81.2M+19.4% | $68.0M+8.5% | $62.6M+4.7% | $59.8M-36.6% | $94.4M+1.6% | $92.9M-0.7% | $93.5M-1.5% | $94.9M+7.4% | $88.4M+67.2% | $52.9M-13.4% | $61.1M+65.4% | $36.9M+5.2% | $35.1M | N/A |
| Total Equity | $1.2B-22.6% | $1.5B+90.0% | $811.0M-26.3% | $1.1B-14.8% | $1.3B+223.4% | $399.5M-37.6% | $640.5M-6.8% | $687.5M+83.1% | $375.5M+4.7% | $358.6M+3.9% | $345.1M-18.7% | $424.4M+222.8% | $131.5M+282.6% | -$72.0M-36.5% | -$52.8M |
| Retained Earnings | -$561.7M-277.2% | -$148.9M+81.9% | -$822.6M-74.8% | -$470.6M-97.1% | -$238.8M+87.0% | -$1.8B-21.6% | -$1.5B-37.2% | -$1.1B-38.4% | -$798.1M-65.2% | -$483.2M-69.7% | -$284.7M-70.5% | -$166.9M-47.2% | -$113.4M-53.2% | -$74.0M | N/A |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
AGIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$360.6M | -$373.0M+4.3% | -$389.8M-31.7% | -$296.1M+4.3% | -$309.5M+24.0% | -$407.3M-40.1% | -$290.8M+21.5% | -$370.6M-21.7% | -$304.4M-6.7% | -$285.2M-839.7% | $38.6M+150.1% | -$76.9M-29.6% | -$59.4M-5.2% | -$56.4M-13.8% | -$49.5M-225.6% | -$15.2M |
| Capital Expenditures | $4.7M | $4.3M+156.1% | $1.7M+68.7% | $999K-79.5% | $4.9M-15.0% | $5.7M-59.3% | $14.1M+17.3% | $12.0M+72.2% | $7.0M+51.0% | $4.6M-53.3% | $9.9M-50.8% | $20.2M+809.9% | $2.2M+71.3% | $1.3M-12.3% | $1.5M-22.6% | $1.9M |
| Free Cash Flow | -$365.3M | -$377.3M+3.6% | -$391.5M-31.8% | -$297.1M+5.5% | -$314.4M+23.9% | -$413.1M-35.5% | -$304.9M+20.3% | -$382.6M-22.9% | -$311.4M-7.4% | -$289.9M-1111.8% | $28.6M+129.5% | -$97.1M-57.7% | -$61.6M-6.7% | -$57.7M-13.1% | -$51.0M-197.9% | -$17.1M |
| Investing Cash Flow | $367.2M | $377.2M+3.8% | $363.4M+51.7% | $239.6M-1.5% | $243.3M-80.5% | $1.2B+1548.6% | $75.7M-17.2% | $91.4M+133.4% | -$273.8M-372.9% | -$57.9M+51.5% | -$119.3M-193.0% | $128.3M | N/A | -$87.2M-478.5% | $23.0M+203.1% | -$22.4M |
| Financing Cash Flow | $12.2M | $8.7M-39.9% | $14.4M+165.8% | $5.4M+131.2% | $2.4M+100.3% | -$765.8M-392.8% | $261.5M-9.7% | $289.6M-47.0% | $546.0M+91.5% | $285.1M+67.9% | $169.8M+2564.0% | $6.4M | N/A | $123.9M+87139.4% | $142K-99.8% | $77.4M |
| Share Buybacks | N/A | N/A | N/A | $0 | $0-100.0% | $802.5M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AGIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3%-0.3pp | 88.6%-0.7pp | 89.3%+1.2pp | 88.0% | N/A | N/A | 98.9%+0.4pp | 98.5%-1.5pp | 100.0%0.0pp | 100.0% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | N/A | N/A | -268.2% | -384.0% | -745.8% | -287.6% | -200.8% | -82.8% | -152.2% | -91.6%-15.4pp | -76.2% |
| Net Margin | -764.4% | 1846.7% | -1312.3% | -1629.2% | N/A | N/A | -349.0% | -366.6% | -731.6% | -284.0% | -199.1% | -81.9% | -154.3% | -80.1% | -108.6% |
| Return on Equity | -34.6%-78.4pp | 43.7%+87.1pp | -43.4%-22.3pp | -21.1%-145.3pp | 124.2%+206.2pp | -81.9%-17.7pp | -64.2%-13.9pp | -50.3%+33.5pp | -83.8%-28.4pp | -55.4%-21.2pp | -34.1%-21.5pp | -12.6%+17.4pp | -30.0% | N/A | N/A |
| Return on Assets | -31.8%-72.4pp | 40.5%+78.1pp | -37.6%-18.8pp | -18.7%-130.4pp | 111.6%+150.0pp | -38.4%+7.8pp | -46.2%-5.9pp | -40.3%+10.9pp | -51.2%-19.2pp | -32.1%-4.0pp | -28.0%-17.1pp | -10.9%+8.7pp | -19.6%-4.9pp | -14.7% | N/A |
| Current Ratio | 11.46-0.4x | 11.90-0.4x | 12.27-1.0x | 13.30-4.5x | 17.79+11.0x | 6.74+0.2x | 6.590.0x | 6.56+1.9x | 4.69-1.6x | 6.330.0x | 6.38+0.5x | 5.89+1.3x | 4.60+0.9x | 3.71 | N/A |
| Debt-to-Equity | 0.090.0x | 0.08-0.1x | 0.160.0x | 0.130.0x | 0.11-1.0x | 1.14+0.7x | 0.39+0.1x | 0.25-0.4x | 0.64-0.1x | 0.73+0.5x | 0.22+0.1x | 0.16-0.4x | 0.53 | N/A | N/A |
| FCF Margin | -698.3% | -1072.7% | -1107.5% | -2207.6% | N/A | N/A | -324.5% | -329.9% | -673.9% | 41.0% | -164.3% | -94.2% | -225.8% | -203.2% | -78.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Agios Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Agios Pharmaceuticals Inc's annual revenue?
Agios Pharmaceuticals Inc (AGIO) reported $54.0M in total revenue for fiscal year 2025. This represents a 48.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Agios Pharmaceuticals Inc's revenue growing?
Agios Pharmaceuticals Inc (AGIO) revenue grew by 48.0% year-over-year, from $36.5M to $54.0M in fiscal year 2025.
Is Agios Pharmaceuticals Inc profitable?
No, Agios Pharmaceuticals Inc (AGIO) reported a net income of -$413.0M in fiscal year 2025.
What is Agios Pharmaceuticals Inc's EBITDA?
Agios Pharmaceuticals Inc (AGIO) had EBITDA of -$466.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Agios Pharmaceuticals Inc's gross margin?
Agios Pharmaceuticals Inc (AGIO) had a gross margin of 88.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Agios Pharmaceuticals Inc's return on equity (ROE)?
Agios Pharmaceuticals Inc (AGIO) has a return on equity of -34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Agios Pharmaceuticals Inc's free cash flow?
Agios Pharmaceuticals Inc (AGIO) recorded an outflow of $377.3M in free cash flow during fiscal year 2025. This represents a 3.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Agios Pharmaceuticals Inc's operating cash flow?
Agios Pharmaceuticals Inc (AGIO) recorded an outflow of $373.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Agios Pharmaceuticals Inc's total assets?
Agios Pharmaceuticals Inc (AGIO) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Agios Pharmaceuticals Inc's capital expenditures?
Agios Pharmaceuticals Inc (AGIO) invested $4.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Agios Pharmaceuticals Inc spend on research and development?
Agios Pharmaceuticals Inc (AGIO) invested $339.5M in research and development during fiscal year 2025.
What is Agios Pharmaceuticals Inc's current ratio?
Agios Pharmaceuticals Inc (AGIO) had a current ratio of 11.46 as of fiscal year 2025, which is generally considered healthy.
What is Agios Pharmaceuticals Inc's debt-to-equity ratio?
Agios Pharmaceuticals Inc (AGIO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Agios Pharmaceuticals Inc's return on assets (ROA)?
Agios Pharmaceuticals Inc (AGIO) had a return on assets of -31.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Agios Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Agios Pharmaceuticals Inc (AGIO) had $89.1M in cash against an annual operating cash burn of $373.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Agios Pharmaceuticals Inc's Altman Z-Score?
Agios Pharmaceuticals Inc (AGIO) has an Altman Z-Score of 10.26, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Agios Pharmaceuticals Inc's Piotroski F-Score?
Agios Pharmaceuticals Inc (AGIO) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Agios Pharmaceuticals Inc's earnings high quality?
Agios Pharmaceuticals Inc (AGIO) reported a net loss of $413.0M while operations used $373.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Agios Pharmaceuticals Inc?
Agios Pharmaceuticals Inc (AGIO) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.